Q4 2023 13F Holders as of 12/31/2023
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
117M
-
Number of holders
-
3
-
Total 13F shares, excl. options
-
320K
-
Shares change
-
+216K
-
Total reported value, excl. options
-
$1.07M
-
Value change
-
+$720K
-
Number of buys
-
3
-
Price
-
$3.33
Significant Holders of Coherus Oncology, Inc. - Common Stock, $0.0001 par value per share (CHRS) as of Q4 2023
3 filings reported holding CHRS - Coherus Oncology, Inc. - Common Stock, $0.0001 par value per share as of Q4 2023.
Coherus Oncology, Inc. - Common Stock, $0.0001 par value per share (CHRS) has 3 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 320K shares
of 117M outstanding shares and own 0.27% of the company stock.
Largest 10 shareholders include BlackRock Inc. (12.1M shares), VANGUARD GROUP INC (10.4M shares), Temasek Holdings (Private) Ltd (7.38M shares), BARCLAYS PLC (3.48M shares), Kohlberg Kravis Roberts & Co. L.P. (3.04M shares), MILLENNIUM MANAGEMENT LLC (2.84M shares), Pictet Asset Management Holding SA (2.48M shares), BANK OF AMERICA CORP /DE/ (2.12M shares), GEODE CAPITAL MANAGEMENT, LLC (2.08M shares), and MORGAN STANLEY (2.07M shares).
This table shows the top 3 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.